This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited and is intended for UK healthcare professionals only.
UK | November 2021 | 165784
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.UK/yellowcard (UK).
If you have a question about a product, please contact Medical Information on 01276 698370 or by email at firstname.lastname@example.org
To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.
Cosentyx (secukinumab) Indications: Treatment of moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy.
Xolair (omalizumab) Indication: Xolair is indicated as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment.